Statin as a Combined Therapy for Advanced-Stage Ovarian Cancer: A Propensity Score Matched Analysis

Abstract EN

Background.

Despite the great achievements in the treatment of advanced-stage ovarian cancer, it is still a severe condition with an unfavorable 5-year survival rate.

Statins have been suggested to reduce the risk of several cancers beyond their cholesterol-lowing effects.

However, the prognostic significance of statins in patients with advanced-stage ovarian cancer remains controversial.

Methods.

A retrospective study was performed to evaluate the association between statin intake and overall survival (OS) among patients with advanced-stage ovarian cancer.

Patients who underwent cytoreductive surgery followed by courses of intravenous chemotherapy were matched through a propensity score analysis.

Results.

A total of 60 propensity-matched patients were included.

Women in statin group showed a similar OS than the nonstatin counterparts (P=0.966), whereas residual tumor was significantly associated with better OS (P=0.013) and was an independent factor that associated with OS (P=0.002, hazard ratio = 5.460, and 95% confidence interval: 1.894 to 15.742) in multivariable analysis.

Conclusions.

Our results suggested that statin usage was not associated with improved OS in patients with advanced-stage ovarian cancer undergoing surgery and chemotherapy.

Considering the retrospective nature and the relative small sample size of the study, further prospective studies and random control trials are needed.